News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
834,266 Results
Type
Article (85746)
Company Profile (755)
Press Release (747765)
Section
Business (232313)
Career Advice (4112)
Deals (39658)
Drug Delivery (122)
Drug Development (90727)
Employer Resources (194)
FDA (17995)
Job Trends (17277)
News (395721)
Policy (39636)
Tag
Academia (2975)
Alliances (56564)
Alzheimer's disease (1365)
Approvals (17917)
Artificial intelligence (178)
Bankruptcy (394)
Best Places to Work (12572)
Biotechnology (519)
Breast cancer (200)
Cancer (1468)
Cardiovascular disease (126)
Career advice (3518)
Cell therapy (324)
Clinical research (72016)
Collaboration (526)
Compensation (269)
COVID-19 (2814)
C-suite (121)
Data (1430)
Diabetes (191)
Diagnostics (6715)
Earnings (94829)
Employer resources (167)
Events (127383)
Executive appointments (415)
FDA (18704)
Funding (460)
Gene therapy (223)
GLP-1 (721)
Government (5056)
Healthcare (20747)
Infectious disease (2916)
Inflammatory bowel disease (126)
Interviews (808)
IPO (17638)
Job creations (5180)
Job search strategy (2856)
Layoffs (495)
Legal (10052)
Lung cancer (218)
Manufacturing (238)
Medical device (14456)
Medtech (14461)
Mergers & acquisitions (22158)
Metabolic disorders (530)
Neuroscience (1724)
NextGen Class of 2024 (7664)
Non-profit (5069)
Northern California (1739)
Obesity (301)
Opinion (249)
Patents (127)
People (64381)
Pharmaceutical (152)
Phase I (22190)
Phase II (31274)
Phase III (23570)
Pipeline (532)
Postmarket research (3549)
Preclinical (10013)
Radiopharmaceuticals (259)
Rare diseases (291)
Real estate (7373)
Regulatory (26121)
Research institute (2643)
Resumes & cover letters (649)
Southern California (1510)
Startups (4276)
United States (16396)
Vaccines (668)
Weight loss (238)
Date
Last 7 days (651)
Last 30 days (2520)
Last 365 days (38104)
2024 (37935)
2023 (42568)
2022 (53928)
2021 (58724)
2020 (57670)
2019 (51341)
2018 (39125)
2017 (37191)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1265)
Arizona (231)
Asia (49504)
Australia (8725)
California (4038)
Canada (1474)
China (322)
Colorado (184)
Connecticut (201)
Europe (113381)
Florida (550)
Georgia (146)
Illinois (466)
Indiana (245)
Maryland (685)
Massachusetts (3231)
Michigan (195)
Minnesota (317)
New Jersey (1161)
New York (1127)
North Carolina (887)
Northern California (1739)
Ohio (156)
Pennsylvania (955)
South America (1647)
Southern California (1510)
Texas (597)
Utah (116)
Washington State (441)
834,266 Results for "'".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Bloom Burton & Co. Inc. Announces Changes to Holdings in Satellos Bioscience Inc.
December 20, 2024
·
2 min read
Press Releases
European Wellness Biomedical Group Announces New Klotho Research Initiative Led by Prof. Mike Chan
December 20, 2024
·
4 min read
GLP-1
Novo’s CagriSema Blunder Underscores Sky-High Investor Expectations for Weight Loss Drugs
Novo Nordisk executives set a high bar for itself when it projected CagriSema could achieve 25% weight loss. When the GLP-1 combo didn’t hit that mark, investors reeled.
December 20, 2024
·
3 min read
·
Annalee Armstrong
MASH
Phase III MASH Miss Sends Galectin Stock Tumbling
Galectin’s shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint for its Phase IIb/III trial for patients with a type of liver cirrhosis.
December 20, 2024
·
1 min read
·
Kate Goodwin
Ovarian cancer
GSK Posts Mixed Survival Data for Jemperli/Zejula Combo in First-Line Ovarian Cancer
First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the third quarter.
December 20, 2024
·
2 min read
·
Tristan Manalac
Press Releases
NervGen Announces “At-The-Market” Equity Program
December 20, 2024
·
7 min read
Press Releases
Alignment Healthcare to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 20, 2024
·
1 min read
Press Releases
iSpecimen Will Serve as a Preferred Provider of Cancer Biospecimens
December 20, 2024
·
2 min read
Press Releases
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
December 20, 2024
·
5 min read
Press Releases
RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial
December 20, 2024
·
3 min read
1 of 83,427
Next
